217 related articles for article (PubMed ID: 31894340)
1. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway.
Liu H; Liu C; Wang M; Sun D; Zhu P; Zhang P; Tan X; Shi G
Sci Rep; 2021 Sep; 11(1):19268. PubMed ID: 34588580
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
4. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines.
Wang L; Wu J; Lu J; Ma R; Sun D; Tang J
Mol Med Rep; 2015 Feb; 11(2):931-9. PubMed ID: 25355053
[TBL] [Abstract][Full Text] [Related]
6. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
7. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.
Lv C; Zeng HW; Wang JX; Yuan X; Zhang C; Fang T; Yang PM; Wu T; Zhou YD; Nagle DG; Zhang WD
Cell Death Dis; 2018 Feb; 9(2):165. PubMed ID: 29416003
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells.
Jiang Y; Bi Y; Zhou L; Zheng S; Jian T; Chen J
BMC Complement Med Ther; 2024 Jan; 24(1):68. PubMed ID: 38297301
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo.
Su CC; Chiu TL
Oncol Rep; 2016 Aug; 36(2):1173-9. PubMed ID: 27277844
[TBL] [Abstract][Full Text] [Related]
10. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
Wu JH; Shi FF; Gong YP; Shi R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer.
Liu Z; Zhu W; Kong X; Chen X; Sun X; Zhang W; Zhang R
Oncol Rep; 2019 Nov; 42(5):1893-1903. PubMed ID: 31485631
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
Ding L; Ding L; Wang S; Wang S; Wang W; Wang W; Lv P; Lv P; Zhao D; Zhao D; Chen F; Chen F; Meng T; Meng T; Dong L; Dong L; Qi L; Qi L
Pharmacology; 2017; 99(3-4):188-195. PubMed ID: 27889779
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway.
Li Q; Shen L; Wang Z; Jiang HP; Liu LX
Biomed Pharmacother; 2016 Dec; 84():106-114. PubMed ID: 27643552
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA derivatives induced S-phase arrest through stabilizing c-myc G-quadruplex DNA to regulate ROS-mediated PI3K/Akt/mTOR pathway.
Wang T; Zou J; Wu Q; Wang R; Yuan CL; Shu J; Zhai BB; Huang XT; Liu NZ; Hua FY; Wang XC; Mei WJ
Eur J Pharmacol; 2021 Dec; 912():174586. PubMed ID: 34710368
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Zhao L; Zhang J; Fan Y; Li Y
Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
Li X; Li Z; Li X; Liu B; Liu Z
BMC Cancer; 2017 May; 17(1):357. PubMed ID: 28532456
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA alleviates acute ethanol-induced myocardial apoptosis mainly through inhibiting the expression of PDCD4 and activating the PI3K/Akt pathway.
Deng H; Yu B; Li Y
Phytother Res; 2021 Aug; 35(8):4309-4323. PubMed ID: 34169595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
